AMN082 – 25 mg

Brand:
Cayman
CAS:
97075-46-2
Storage:
-20
UN-No:
De Minimis - 3077 / 9

AMN082 is an orally bioavailable allosteric agonist of metabotropic glutamate receptor 7 (mGluR7).{47688} It inhibits cAMP accumulation induced by forskolin in CHO cells expressing human mGluR7b (EC50 = 64 nM). AMN082 (10 μM) is selective for mGluR7a and mGluR7b over mGluR1b, mGluR4, and mGluR8a with 140, 90, 15, 18, and 20% activation, respectively, as well as over mGluR2, mGluR3, mGluR5a, mGluR6, GluR3, and NMDA receptors containing NR1a, NR2A, or NR2B subunits. AMN082 also binds to the norepinephrine transporter (NET) and α1-adrenergic receptor (α1-AR).{47689} It increases the proliferation of neural progenitor cells (NPCs) and induces their differentiation into neurons when used at a concentration of 1 μM.{47690} AMN082 (2.5 mg/kg) inhibits apomorphine-induced circling in a rat model of Parkinson’s disease induced by 6-hydroxy dopamine (6-OHDA; Item No. 25330).{47691}  

 

Available on backorder

SKU: 28779 - 25 mg Category:

Description

An allosteric mGluR7 agonist; inhibits forskolin-induced cAMP accumulation in CHO cells expressing human mGluR7b (EC50 = 64 nM); selective for mGluR7a and mGluR7b over mGluR1b, mGluR4, and mGluR8a with 140, 90, 15, 18, and 20% activation, respectively, as well as over mGluR2, mGluR3, mGluR5a, mGluR6, GluR3, and NMDA receptors containing NR1a, NR2A, or NR2B subunits at 10 μM; binds to NET and α1-AR; increases the proliferation NPCs and induces their differentiation into neurons at 1 μM; inhibits apomorphine-induced circling in a 6-OHDA-induced PD rat model at 2.5 mg/kg


Formal name: N,N′-bis(diphenylmethyl)-1,2-ethanediamine, dihydrochloride

Synonyms: 

Molecular weight: 465.5

CAS: 97075-46-2

Purity: ≥98%

Formulation: A crystalline solid